Mirum Pharmaceuticals, a leader in rare disease therapies, has announced that Health Canada has approved the tablet formulation of LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).

 

Previously available in Canada as a liquid solution, LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution.

 

“LIVMARLI’s tablet formulation provides an important new option for patients with ALGS,” said Jamie Twiselton, General Manager, Mirum Pharmaceuticals Canada. “With a liquid formulation for younger patients and a convenient one tablet per dose option available for older patients, LIVMARLI now provides greater dosing flexibility, supporting continuity of care as patients with ALGS age.”

 

ALGS is a rare genetic disorder affecting multiple organs, including the liver, where bile duct abnormalities can trigger cholestasis and severe itching. Chronic pruritus can disrupt sleep, growth, and daily life for patients and their families.

 

“As children with Alagille syndrome grow, treatment needs can change,” said Or Steg Saban, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto. “The availability of a tablet formulation of LIVMARLI in Canada provides an additional option for appropriate patients, which may support treatment adherence and continuity of care while continuing to address cholestatic pruritus.”